https://www.live-feeds.com/feed/novartis-cholesterol-setback-tests-hopes-for-emerging-heart-disease-drugsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-cholesterol-setback-tests-hopes-for-emerging-heart-disease-drugshttps://www.live-feeds.com/feed/novartis-cholesterol-setback-tests-hopes-for-emerging-heart-disease-drugs#u65167Fri, 11 Sep 2026 14:30:09 +0000Novartis shares fell 10% following the failure of its Lp(a) drug pelacarsen in a Phase 3 trial designed to lower cardiovascular risk. The negative outcome triggered a broader selloff affecting Ionis and Amgen, driven by investor concerns regarding an entire class of emerging heart medicines. Cardiologists previously anticipated the drug would act as a major defense against heart attacks. This unexpected trial result marks part of a severe week for Novartis, which has endured three trial failures and headed toward its worst trading day on record.Why it mattersPharmaceutical companies have poure https://www.live-feeds.com/feed/novartis-cholesterol-setback-tests-hopes-for-emerging-heart-disease-drugshttps://www.live-feeds.com/feed/novartis-cholesterol-setback-tests-hopes-for-emerging-heart-disease-drugs#u62270Wed, 09 Sep 2026 04:06:37 +0000Novartis shares dropped 10% after its Lp(a) drug, pelacarsen, failed a Phase 3 trial to lower cardiovascular risk. The result has triggered a selloff for Novartis, Ionis, and Amgen, as investors fear the failure reflects a broader issue with an emerging class of heart medicines. This setback is part of a difficult week for Novartis, which has faced three drug trial failures, leading the company toward its worst day on record. The outcome has shocked cardiologists and raised questions about the viability of similar competing products currently in development.Why it mattersLp(a) drugs target a s